You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial

Gilead Sciences and MSD – known as Merck in the US and Canada – have announced a clinical trial collaboration to test a combination of Gilead’s Trodelvy and MSD’s Keytruda for the first-line treatment of certain triple-negative breast cancer (TNBC) patients.